{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:26:19Z","timestamp":1793316379749,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"02","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Glob Med Genet"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background\u2003Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm with features of the myelodysplastic syndromes (MDSs) and myeloproliferative neoplasm presenting with peripheral blood monocytosis and an inherent risk for transformation to acute myeloid leukemia, while the abnormal DNA methylation plays a critical role in the pathogenesis of MDS, which is a disease of disordered differentiation. Recently, with the rapid development of molecular biology, hypomethylating agents (HMAs) for the treatment of MDS has gradually become a research focus. The objective of this study was to evaluate the benefits and risks of HMAs for patients with CMML.<\/jats:p><jats:p>Materials and Methods\u2003PubMed, Embase, the Cochrane Library, and three Chinese databases were searched for studies published before November 2020 that used HMAs in CMML.<\/jats:p><jats:p>Results\u2003The pooled objective response rate (ORR), complete response (CR), and partial response (PR) were 50.0, 21.0, and 2.0%, respectively. The proportion of patients with minor response (MR) was significantly higher for decitabine (DAC) than for azacitidine (AZA). There was no significant difference in hematologic improvement, ORR, CR, and PR rates between the DAC and AZA groups. Hematological toxicity included neutropenia grade 3\/4 (14.0%), anemia grade 3\/4 (17.0%), and thrombocytopenia grade 3\/4 (22.0%).<\/jats:p><jats:p>Conclusion\u2003This study showed that HMAs were effective and safe in the treatment of CMML, but large multicenter study would be needed to confirm the efficacy of HMAs for the treatment of CMML with different risk level and genetic abnormality, to support individualization treatment theoretically.<\/jats:p>","DOI":"10.1055\/s-0042-1744157","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T22:51:10Z","timestamp":1649458270000},"page":"141-151","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Hypomethylating Agents in Chronic Myelomonocytic Leukemia: A Single-Arm Meta-analysis"],"prefix":"10.1016","volume":"09","author":[{"given":"Xinhui","family":"Zheng","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwei","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Hematology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erlie","family":"Jiang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.beha.2013.09.006","article-title":"Chronic myelomonocytic leukemia: myelodysplastic or myeloproliferative?","volume":"26","author":"R Itzykson","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"issue":"20","key":"ref2","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"D A Arber","year":"2016","journal-title":"Blood"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"H Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1705369","article-title":"Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia","volume":"37","author":"M A Elliott","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"05","key":"ref5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ejh.12073","article-title":"Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"90","author":"S Park","year":"2013","journal-title":"Eur J Haematol"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3310\/hta14Suppl1-10","article-title":"Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia","volume":"14","author":"R Edlin","year":"2010","journal-title":"Health Technol Assess"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.beha.2012.10.007","article-title":"Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?","volume":"25","author":"D P Steensma","year":"2012","journal-title":"Best Pract Res Clin Haematol"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41408-018-0085-4","article-title":"Myelodysplastic syndromes current treatment algorithm 2018","volume":"8","author":"D P Steensma","year":"2018","journal-title":"Blood Cancer J"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CCO.0000000000000486","article-title":"Current management of patients with chronic myelomonocytic leukemia","volume":"30","author":"E Mora","year":"2018","journal-title":"Curr Opin Oncol"},{"issue":"06","key":"ref10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s11899-017-0416-8","article-title":"Models of prognostication in chronic myelomonocytic leukemia","volume":"12","author":"F Onida","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"issue":"09","key":"ref11","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"K Slim","year":"2003","journal-title":"ANZ J Surg"},{"issue":"02","key":"ref12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"B D Cheson","year":"2006","journal-title":"Blood"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/leu.2017.186","article-title":"A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia","volume":"32","author":"V Santini","year":"2018","journal-title":"Leukemia"},{"issue":"07","key":"ref14","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2014.85","article-title":"A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia","volume":"28","author":"M W Drummond","year":"2014","journal-title":"Leukemia"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"P W Wijermans","year":"2008","journal-title":"Leuk Res"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.3109\/10428194.2016.1138295","article-title":"A phase II study of the efficacy, safety, and determinants of response to 5-azacitidine (Vidaza\u00ae) in patients with chronic myelomonocytic leukemia","volume":"57","author":"S K Tantravahi","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"07","key":"ref17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ajh.24735","article-title":"Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents","volume":"92","author":"A Alfonso","year":"2017","journal-title":"Am J Hematol"},{"issue":"07","key":"ref18","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/ajh.25488","article-title":"Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients","volume":"94","author":"T Coston","year":"2019","journal-title":"Am J Hematol"},{"issue":"07","key":"ref19","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/10428194.2018.1540783","article-title":"Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system","volume":"60","author":"P T Diamantopoulos","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"03","key":"ref20","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s12253-018-00574-0","article-title":"Real life data on efficacy and safety of azacitidine therapy for myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia","volume":"25","author":"G Helbig","year":"2019","journal-title":"Pathol Oncol Res"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.leukres.2014.01.006","article-title":"Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival","volume":"38","author":"L Pleyer","year":"2014","journal-title":"Leuk Res"},{"issue":"01","key":"ref22","doi-asserted-by":"crossref","first-page":"e2014020","DOI":"10.4084\/mjhid.2014.020","article-title":"Azacitidine in chronic myelomonocytic leukemia: an effective and manageable approach","volume":"6","author":"A Tendas","year":"2014","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3109\/10428194.2012.719617","article-title":"High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study","volume":"54","author":"L Fianchi","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3109\/10428194.2012.730615","article-title":"Treatment of chronic myelomonocytic leukemia with azacitidine","volume":"54","author":"E Wong","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"08","key":"ref25","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.leukres.2012.04.024","article-title":"Treatment of chronic myelomonocytic leukemia with 5-azacitidine: a case series and literature review","volume":"36","author":"M Thorpe","year":"2012","journal-title":"Leuk Res"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"R Costa","year":"2011","journal-title":"Cancer"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia","volume":"109","author":"A Aribi","year":"2007","journal-title":"Cancer"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"L R Silverman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"08","key":"ref30","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"H Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12878-017-0094-8","article-title":"Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia","volume":"18","author":"R M Shapiro","year":"2018","journal-title":"BMC Hematol"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00277-017-3102-y","article-title":"A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis","volume":"96","author":"B Yang","year":"2017","journal-title":"Ann Hematol"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/1535-7163.MCT-08-0743","article-title":"Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation","volume":"8","author":"M Rius","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"02","key":"ref34","doi-asserted-by":"crossref","first-page":"e9001","DOI":"10.1371\/journal.pone.0009001","article-title":"A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines","volume":"5","author":"P W Hollenbach","year":"2010","journal-title":"PLoS One"},{"issue":"34","key":"ref35","doi-asserted-by":"crossref","first-page":"e11860","DOI":"10.1097\/MD.0000000000011860","article-title":"Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: a systematic review and meta-analysis","volume":"97","author":"C Gao","year":"2018","journal-title":"Medicine (Baltimore)"}],"container-title":["Global Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0042-1744157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T15:22:42Z","timestamp":1736436162000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0042-1744157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":34,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2022,6,13]]},"published-print":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0042-1744157","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2699-9404"],"issn-type":[{"value":"2699-9404","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]}}}